This Is Your Brain on (Anti-Obesity) Drugs

Medications targeting the glucagon-like peptide-1 (GLP-1) receptor have been used for decades to treat diabetes, but more recently have revolutionized obesity pharmacotherapies. During this webinar, Dr. Elizabeth Mietlicki-Baase, PhD '11, MA '09, from the UB Department of Exercise and Nutrition, will share insights into the mechanisms underlying the ability of these drugs to suppress feeding and reduce body weight, as well as consider emerging pharmacological approaches to treating obesity and discuss how these differ from currently available GLP-1 agonists. 

About Elizabeth Mietlicki-Baase
Dr. Elizabeth Mietlicki-Baase is an Associate Professor in the Department of Exercise and Nutrition Sciences at the University at Buffalo. She earned her PhD in Behavioral Neuroscience at the University at Buffalo, followed by postdoctoral training in the Department of Psychiatry at the University of Pennsylvania. Dr. Mietlicki-Baase’s research focuses on the neural controls of energy balance and motivated behavior. She is particularly interested in understanding how feeding-relevant hormones act in the reward systems of the brain to control food intake, body weight, and motivation for palatable foods. She is a Buffalo native and her favorite palatable hometown food is pizza and wings (extra crispy please!).